Coherus Oncology (CHRS) Operating Margin (QoQ) (2013 - 2026)

Coherus Oncology (CHRS) Operating Margin (QoQ) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Coherus Oncology 194.37 Mn 27.32 Mn 8.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 6,623.00
Dec 31, 2025 2,324.00
Sep 30, 2025 6,045.00
Jun 30, 2025 15,431.00
Mar 31, 2025 -1,102.00
Dec 31, 2024 18,734.00
Sep 30, 2024 -38,936.00
Jun 30, 2024 255,218.00
Mar 31, 2024 -286,176.00
Dec 31, 2023 -3,236.00
Sep 30, 2023 1,591.00
Jun 30, 2023 15,003.00
Mar 31, 2023 -9,532.00
Dec 31, 2022 6,357.00
Sep 30, 2022 -10,394.00
Jun 30, 2022 6,145.00
Mar 31, 2022 -8,070.00
Dec 31, 2021 -1,417.00
Sep 30, 2021 -1,217.00
Jun 30, 2021 17,399.00